Form 4: Carisma Therapeutics Inc. Director Acquires Stock Options

Director Briggs Morrison acquired 19,350 stock options in Carisma Therapeutics Inc. on June 26, 2024.

Summary

• On June 26, 2024, Briggs Morrison, a director of Carisma Therapeutics Inc., acquired 19,350 stock options.
• The exercise price of these options is $1.22.
• The options vest on the first anniversary of the grant date or immediately before the first annual meeting of stockholders after the grant date, contingent on continued service as a director.
• The options expire on June 26, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants to a director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of the shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options to align their interests with shareholders.
• The vesting schedule and exercise price are typical for such grants.
• Similar grants are common among comparable companies in the biotechnology sector.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates